MX365621B - Nueva combinacion. - Google Patents
Nueva combinacion.Info
- Publication number
- MX365621B MX365621B MX2014007700A MX2014007700A MX365621B MX 365621 B MX365621 B MX 365621B MX 2014007700 A MX2014007700 A MX 2014007700A MX 2014007700 A MX2014007700 A MX 2014007700A MX 365621 B MX365621 B MX 365621B
- Authority
- MX
- Mexico
- Prior art keywords
- new combination
- pimobendan
- benazepril
- relates
- new
- Prior art date
Links
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 abstract 1
- 229960004530 benazepril Drugs 0.000 abstract 1
- 229940000425 combination drug Drugs 0.000 abstract 1
- 229960002164 pimobendan Drugs 0.000 abstract 1
- GLBJJMFZWDBELO-UHFFFAOYSA-N pimobendane Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC=C(C=3C(CC(=O)NN=3)C)C=C2N1 GLBJJMFZWDBELO-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Edible Oils And Fats (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11195015 | 2011-12-21 | ||
| EP12185714 | 2012-09-24 | ||
| PCT/EP2012/076100 WO2013092673A2 (en) | 2011-12-21 | 2012-12-19 | New combination |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014007700A MX2014007700A (es) | 2014-08-21 |
| MX365621B true MX365621B (es) | 2019-06-07 |
Family
ID=47552987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014007700A MX365621B (es) | 2011-12-21 | 2012-12-19 | Nueva combinacion. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10874618B2 (enExample) |
| EP (3) | EP3034071B1 (enExample) |
| JP (1) | JP6148252B2 (enExample) |
| CN (1) | CN104010632B (enExample) |
| AU (1) | AU2012357795B2 (enExample) |
| BR (1) | BR112014014896A2 (enExample) |
| CA (1) | CA2858941C (enExample) |
| CL (1) | CL2014001534A1 (enExample) |
| CO (1) | CO6970601A2 (enExample) |
| CY (1) | CY1117086T1 (enExample) |
| DK (2) | DK3034071T3 (enExample) |
| ES (2) | ES2560052T5 (enExample) |
| HR (1) | HRP20151347T1 (enExample) |
| HU (2) | HUE028579T2 (enExample) |
| MX (1) | MX365621B (enExample) |
| NO (1) | NO3034071T3 (enExample) |
| PL (2) | PL2793866T5 (enExample) |
| PT (1) | PT3034071T (enExample) |
| RS (1) | RS54475B1 (enExample) |
| RU (1) | RU2014129508A (enExample) |
| SI (1) | SI2793866T1 (enExample) |
| WO (1) | WO2013092673A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
| EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
| RS54475B1 (sr) | 2011-12-21 | 2016-06-30 | Novartis Tiergesundheit Ag | Nova kombinacija |
| ES2924478T3 (es) | 2012-03-15 | 2022-10-07 | Boehringer Ingelheim Vetmedica Gmbh | Formulación de comprimidos farmacéuticos para el sector médico veterinario, método de producción y uso de los mismos |
| JP6272475B2 (ja) | 2013-07-19 | 2018-01-31 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ | 防腐エーテル化シクロデキストリン誘導体含有液体水性医薬組成物 |
| CN110721164B (zh) * | 2013-12-04 | 2024-09-17 | 勃林格殷格翰动物保健有限公司 | 匹莫苯的改善的药物组合物 |
| US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
| CN112618505B (zh) * | 2020-12-30 | 2022-11-15 | 南京朗博特动物药业有限公司 | 一种宠物用含有贝那普利和匹莫苯丹的复方药物组合物及其制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5364646A (en) | 1990-01-10 | 1994-11-15 | Dr. Karl Thomae Gmbh | Oral pharmaceutical forms of pimobendan |
| US6162802A (en) | 1992-03-10 | 2000-12-19 | Papa; Joseph | Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor |
| WO2002049645A1 (en) * | 2000-12-18 | 2002-06-27 | Novartis Ag | Therapeutic combination of amlodipine and benazepril |
| AU2003217916A1 (en) | 2002-03-08 | 2003-09-22 | Teva Pharmeceuticals Usa, Inc. | Stable formulations of angiotensin converting enzyme (ace) inhibitors |
| CO5400144A1 (es) | 2002-03-11 | 2004-05-31 | Novartis Ag | Compuestos organicos |
| AU2004281541B2 (en) * | 2003-10-20 | 2008-05-01 | Novartis Ag | Tbenazpril and amlodipine for reducing cardiovascular morbidity |
| GB2394660A (en) | 2003-12-17 | 2004-05-05 | Niche Generics Ltd | Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide |
| DE102004011512B4 (de) | 2004-03-08 | 2022-01-13 | Boehringer Ingelheim Vetmedica Gmbh | Pharmazeutische Zubereitung enthaltend Pimobendan |
| US8980894B2 (en) * | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
| JP2005281283A (ja) | 2004-03-31 | 2005-10-13 | Akira Matsumori | ベンズイミダゾール系薬剤の併用医薬 |
| US20080268049A1 (en) * | 2005-02-11 | 2008-10-30 | Dhaliwal Mona | Stable Solid Dosage Forms of Amlodipine and Benazepril |
| JP2010500374A (ja) * | 2006-08-08 | 2010-01-07 | エーシーシーユー−ブレイク テクノロジーズ，インク． | 複数の活性セグメントを含む薬剤の錠剤 |
| AU2008213744B2 (en) | 2007-02-09 | 2013-12-05 | Alphapharm Pty Ltd | A dosage form containing two or more active pharmaceutical ingredients in different physical forms |
| FR2917975B1 (fr) | 2007-06-26 | 2009-10-16 | Ceva Sante Animale Sa | Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains |
| WO2010055119A2 (en) | 2008-11-17 | 2010-05-20 | Novartis Ag | Pharmaceutical composition comprising pimobendan |
| WO2010097501A2 (en) | 2009-02-26 | 2010-09-02 | Orion Corporation | A combination treatment |
| WO2011111066A2 (en) | 2010-03-12 | 2011-09-15 | Connexios Life Sciences Pvt. Ltd. | Composition and uses thereof |
| RS54475B1 (sr) | 2011-12-21 | 2016-06-30 | Novartis Tiergesundheit Ag | Nova kombinacija |
-
2012
- 2012-12-19 RS RS20150850A patent/RS54475B1/sr unknown
- 2012-12-19 NO NO15193269A patent/NO3034071T3/no unknown
- 2012-12-19 ES ES12813324T patent/ES2560052T5/es active Active
- 2012-12-19 PL PL12813324.6T patent/PL2793866T5/pl unknown
- 2012-12-19 HU HUE12813324A patent/HUE028579T2/en unknown
- 2012-12-19 EP EP15193269.6A patent/EP3034071B1/en active Active
- 2012-12-19 EP EP17199031.0A patent/EP3320894A1/en not_active Withdrawn
- 2012-12-19 US US14/366,900 patent/US10874618B2/en active Active
- 2012-12-19 JP JP2014547959A patent/JP6148252B2/ja active Active
- 2012-12-19 CN CN201280062716.3A patent/CN104010632B/zh active Active
- 2012-12-19 EP EP12813324.6A patent/EP2793866B2/en active Active
- 2012-12-19 PL PL15193269T patent/PL3034071T3/pl unknown
- 2012-12-19 HR HRP20151347TT patent/HRP20151347T1/hr unknown
- 2012-12-19 BR BR112014014896A patent/BR112014014896A2/pt active Search and Examination
- 2012-12-19 DK DK15193269.6T patent/DK3034071T3/en active
- 2012-12-19 HU HUE15193269A patent/HUE035830T2/en unknown
- 2012-12-19 ES ES15193269.6T patent/ES2656412T3/es active Active
- 2012-12-19 PT PT151932696T patent/PT3034071T/pt unknown
- 2012-12-19 AU AU2012357795A patent/AU2012357795B2/en active Active
- 2012-12-19 RU RU2014129508A patent/RU2014129508A/ru unknown
- 2012-12-19 CA CA2858941A patent/CA2858941C/en active Active
- 2012-12-19 WO PCT/EP2012/076100 patent/WO2013092673A2/en not_active Ceased
- 2012-12-19 DK DK12813324.6T patent/DK2793866T4/da active
- 2012-12-19 SI SI201230374T patent/SI2793866T1/sl unknown
- 2012-12-19 MX MX2014007700A patent/MX365621B/es active IP Right Grant
-
2014
- 2014-06-03 CO CO14118785A patent/CO6970601A2/es active IP Right Grant
- 2014-06-11 CL CL2014001534A patent/CL2014001534A1/es unknown
-
2015
- 2015-12-30 CY CY20151101200T patent/CY1117086T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN02639A (enExample) | ||
| MX365621B (es) | Nueva combinacion. | |
| GB201114103D0 (en) | Novel compounds | |
| GB201106799D0 (en) | Novel compounds | |
| GB201107325D0 (en) | Novel compounds | |
| GB201116641D0 (en) | Novel compounds | |
| GB201112607D0 (en) | Novel compounds | |
| EP2717694A4 (en) | NEW COMPOUNDS | |
| GB201111704D0 (en) | Novel compounds | |
| GB201122113D0 (en) | Novel compounds | |
| IN2015DN00725A (enExample) | ||
| UA103722C2 (ru) | Огнеупорный керамический ударопоглощающий стакан | |
| IN2012DE02272A (enExample) | ||
| AU332622S (en) | A fork | |
| AU332619S (en) | A fork | |
| AU332616S (en) | A fork | |
| IN2011KO00551A (enExample) | ||
| UA72478U (ru) | Применение полентара как средства фригопротекторного действия | |
| UA94339C2 (ru) | применение корвитина в качестве средства фригопротекторного действия | |
| IN2011KO01200A (enExample) | ||
| AU2012900542A0 (en) | P-glycoprotein polymorphisms predict antidepressant dose needed to remit. | |
| GB201119590D0 (en) | New compounds I | |
| GB201114399D0 (en) | Novel compounds | |
| GB201111476D0 (en) | Novel compounds | |
| GB201121360D0 (en) | Novel compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: ELANCO TIERGESUNDHEIT AG |
|
| HC | Change of company name or juridical status |
Owner name: ELANCO TIERGESUNDHEIT AG |
|
| FG | Grant or registration |